Wedbush downgraded Freeline Therapeutics to Neutral from Outperform with a price target of $5, down from $8.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FRLN:
- Freeline to present new clinical data for FLT201 at ESGCT Congress
- Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress
- Stifel keeps Hold on Freeline despite positive Phase 1/2 GALILEO-1 update
- Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
- Freeline reports initial data from first cohort of Phase 1/2 GALILEO-1 trial